Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors

Abstract

Gastrointestinal stromal tumors (GISTs) are frequently driven by auto-activated, mutant KIT and have durable response to KIT tyrosine kinase inhibitor. However, acquired resistance is an increasing clinical issue in GIST patients receiving front-line imatinib therapy. Our previous studies showed the colocalization of KIT with DAPI-stained nuclei in GIST cells without knowing the role of nuclear KIT in GIST tumorigenesis. In this article, we first identified the binding of nuclear KIT to the promoter of NFKB inhibitor beta (NFKBIB) by chromatin immunoprecipitation (ChIP) sequencing and ChIP assays, which was accompanied with enhanced NFKBIB protein expression in GIST cells. Clinically, high NCCN risk GISTs had significantly higher mean expression levels of nuclear phospho-KIT and NFKBIB as compared with those of intermediate or low/very low-risk GISTs. Conversely, downregulation of NFKBIB by siRNA led to RELA nuclear translocation that could bind to the KIT promoter region and subsequently reduced KIT transcription/expression and the viability of GIST cells. These findings were further confirmed by either RELA overexpression or NFKB/RELA inducer, valproic acid, treatment to result in reduced KIT expression and relative cell viability of imatinib-resistant GIST cells. Combining valproic acid with imatinib showed significantly better growth inhibitory effects on imatinib-resistant GIST48 and GIST430 cells in vitro, and in the GIST430 animal xenograft model. Taken together, these results demonstrate the existence of a nuclear KIT-driven NFKBIB-RELA-KIT autoregulatory loop in GIST tumorigenesis, which are potential targets for developing combination therapy to overcome imatinib-resistant of KIT-expressing GISTs.

AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression

“…Cell component separation and immunofluorescence stains demonstrated that AXL and p53 have nuclear colocalization ( Figure 4 A,B). Various studies have shown that nuclear translocation of RTKs (full-length or truncated) by c-secretase cleavage of the full-length receptor, shedding, alternative splicing, or alternative translation initiation, including EGFR, ERBB2, FGFR1, KIT, and AXL, regulates transcription [ 32 , 33 , 34 , 35 , 36 , 37 ]. A recent report found that AXL, but not the other two members of the same family MERTK or TYRO3, is cleaved by α- and γ-secretases in cancer cell lines to generate an AXL intracellular isoform.…”

Overview of current targeted therapy in gallbladder cancer

“…[330][331][332][333] Typical therapeutic blocking agents employed to target KIT include cabozantinib, dovitinib, masitinib, and pazopanib. [334][335][336] At present, two additional clinical trials (NCT01153750, NCT02115542) wait for final results.…”

Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity

“… 10 In many different cancer types, networks of oncogenic master TFs form autoregulatory loops via each other’s SEs. 32 , 33 , 34 , 35 , 36 , 37 Disruption of a single oncogenic master TF is often sufficient to collapse this circuitry, leading to cell death or differentiation. We hypothesize that transcriptional inhibition achieves a therapeutic effect by targeting oncogenic TF autoregulation and inducing selective downregulation of these genes.…”